Activity of manganese superoxide dismutase (MnSOD) as a predictor of radiation therapy outcome in patients with stage IIIB squamous cell carcinoma cervical cancer

  • Fitriyadi Kusuma Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Romi Saut Halomoan Sinaga Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Ani Retno Prijanti Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Aria Kekalih Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Sri Mulya Sekarutami Department of Radiotherapy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
DOI: https://doi.org/10.13181/mji.v28i2.2929
Keywords: cervical cancer, MnSOD, radiotherapy, squamous cell carcinoma, uterine cervical neoplasms
Abstract viewed: 716 times
PDF downloaded: 695 times
HTML downloaded: 119 times
EPUB downloaded: 255 times

Abstract

BACKGROUND Radiation is a standard therapy for cervical cancer. Unfortunately, not all patients undergoing radiation achieve a complete response. Previous studies have shown that manganese superoxide dismutase (MnSOD) acts against free radicals generated by radiation in cancer cells thus predicting worse outcome in radiation therapy. This study was aimed to assess and evaluate whether MnSOD activity can be used as a predictor of radiation therapy responses in patients with stage IIIB squamous cell carcinoma (SCC).

METHODS A comparative cross-sectional study was conducted in the Gynecology Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta. The database from previous research was analyzed to identify positive and negative response samples. Measurement of MnSOD activity was done using spectrophotometry based on the McCord and Fridovich method using RanSOD® kit. The comparative data were obtained and then analyzed.

RESULTS Among 76 samples, 49 (61.8%) patients had positive responses and 27 (38.2%) had negative responses. It is shown in this study that higher MnSOD activity is related to worse radiotherapy outcome in stage IIIB cancer patients. The relative risk value of having a worse outcome with high MnSOD activity is 1.849 (1.075-3.178, 95% CI).

CONCLUSIONS Stage IIIB squamous cell carcinoma patients with high MnSOD activity are at higher risk of having a negative radiation therapy response compared with patients without high MnSOD activity.

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. https://doi.org/10.1002/ijc.29210

  2. Staging Cervix [Internet]. Indonesian society of gynecologic oncology (INASGO). 2015.

  3. Di Saia P, Creasman W. Clinical gynecologic oncology. 8th ed. Philadelphia: Elsevier Inc.; 2012. 98 p.

  4. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv72-83. https://doi.org/10.1093/annonc/mdx220

  5. Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med 2009;47(4):344-56. https://doi.org/10.1016/j.freeradbiomed.2009.05.018

  6. . Matés JM. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 2000;153(1-3)83-104. https://doi.org/10.1016/S0300-483X(00)00306-1

  7. Nelson KK, Ranganathan AC, Mansouri J, Rodriguez AM, Providence KM, Rutter JL, et al. Elevated SOD2 activity augments matrix metalloproteinase expression: evidence for the involvement of endogenous hydrogen peroxide in regulating metastasis. Clin Cancer Res 2003;9(1):424-32.

  8. Nakano T, Oka K, Taniguchi N. Manganese superoxide dismutase expression correlates with p53 status and local recurrence of cervical carcinoma treated with radiation therapy. Cancer Res 1996;56(12):2771-5.

  9. Kusuma F, Andrijono, Nuranna L, Prijanti AR, Sekarutami SM. Levels of Survivin, Telomerase and Cytochrome C as Predictors of Therapeutic Response in Patients with Stage IIIB Squamous Cell Carcinoma of Cervix. PhD [Dissertation]. Jakarta: Faculty of Medicine Universitas Indonesia; 2017.

  10. Aziz MF. Gynecological cancer in Indonesia. J Gynecol Oncol. 2009;20(1):8-10. https://doi.org/10.3802/jgo.2009.20.1.8

  11. Catheryn M. Yashar. Clinical Gynecologic Oncology. 8th ed. Philadelphia: Elsevier Inc.; 2012. 98 p.

  12. Sekarutami SM, Gondhowiardjo S, Aziz F, Sregar NC, Harahap A. Effects of hypoxia on angiogenesis and proliferation-correlation with tumor response in patients with cervical cancer treated with combined radiation and carbogen=nicotinamide. Ejc Suppl. 2011;1-23:22-3. https://doi.org/10.1016/j.ejcsup.2011.02.057

  13. Xiang T, Du L, Pham P, Zhu B, Jiang S. Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway. Cancer Lett 2015;364(1):79-88. https://doi.org/10.1016/j.canlet.2015.04.027

Published
2019-08-09
How to Cite
1.
Kusuma F, Sinaga RSH, Prijanti AR, Kekalih A, Sekarutami SM. Activity of manganese superoxide dismutase (MnSOD) as a predictor of radiation therapy outcome in patients with stage IIIB squamous cell carcinoma cervical cancer. Med J Indones [Internet]. 2019Aug.9 [cited 2024Apr.25];28(2):141-5. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/2929
Issue
Vol. 28 No. 2 (2019): June
Section
Clinical Research

Copyright (c) 2019 Fitriyadi Kusuma, Romi SH Sinaga, Ani Retno Prijanti, Aria Kekalih, Sri Mulya Sekarutami

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.